Clearside Biomedical, Inc. (CLSD)
| Market Cap | 333.09M |
| Revenue (ttm) | 4.26M |
| Net Income (ttm) | -22.99M |
| Shares Out | 57.75M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 408,840 |
| Open | 5.52 |
| Previous Close | 5.60 |
| Day's Range | 5.34 - 5.76 |
| 52-Week Range | 1.25 - 7.73 |
| Beta | 1.78 |
| Analysts | Buy |
| Price Target | 11.60 (+103.2%) |
| Est. Earnings Date | Nov 9, 2021 |
About CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in...
Financial Performance
In 2020, CLSD's revenue was $7.89 million, an increase of 263.28% compared to the previous year's $2.17 million. Losses were -$18.21 million, -40.82% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is 11.60, which is an increase of 103.15% from the latest price.
News
Clearside Biomedical Delivers Podium and Poster Presentations at the American Society of Retina Specialists (ASRS) An...
Multiple clinical data presentations demonstrate the potential of the suprachoroidal injection platform as a flexible, in-office, non-surgical procedure across multiple chorioretinal diseases Multiple c...
7 Top-Rated Pharmaceutical Stocks To Invest in for October
It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared first ...
Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting
ALPHARETTA, Ga., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib inje...
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visi...
Clearside Biomedical Expands XIPERE™ License Agreement with Arctic Vision to Include Australia, New Zealand, India an...
– Increasing Global Awareness of Innovative Suprachoroidal Injection Platform – – Increasing Global Awareness of Innovative Suprachoroidal Injection Platform –
Clearside Biomedical to Present at the Ophthalmology Futures European 2021 Virtual Retina Forum
ALPHARETTA, Ga., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ...
SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agr...
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 8.33% and 5.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical: Q2 Earnings Insights
Shares of Clearside Biomedical (NASDAQ:CLSD) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 15.38% over the past year to ($0.11), w...
Clearside Biomedical Announces Second Quarter 2021 Financial Results and Provides Corporate Update
- Enrollment Underway in Cohort 2 of OASIS Wet AMD Phase 1/2a Trial with Data Expected by the End of 2021 –
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021
ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...
Will Clearside Biomedical, Inc. (CLSD) Report Negative Earnings Next Week? What You Should Know
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August ...
ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...
Which Penny Stocks Are Investors Buying Right Now? Check These 7 Out
Looking for the best penny stocks to watch right now? Check these 7 out The post Which Penny Stocks Are Investors Buying Right Now?
Penny Stocks to Watch With AMC Stock Back in Focus
In a recent pennystocks.com article, we covered 5 Penny Stocks on Reddit for Your June 2021 Watchlist. This piece is a continuation, as more and more valuable penny stocks continue to come to light. Rig...
Why Clearside Biomedical Stock Surged Today
Analysts are excited about the biotech's investigational treatment for a common eye disorder.
4 Penny Stocks Reddit Traders Are Buying Right Now
Looking for penny stocks to buy on Reddit? Check these 4 out for your watchlist The post 4 Penny Stocks Reddit Traders Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...
Do Options Traders Know Something About Clearside Biomedical (CLSD) Stock We Don't?
Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.
CLSD Stock: The Big News Lifting Clearside Biomedical Today
Today, investors in CLSD stock are seeing gains of nearly 50% as the company announced positive results from one of its clinical trials. The post CLSD Stock: The Big News Lifting Clearside Biomedical To...
Where Will The Clearside Biomedical Stock Rally End?
Shares of Clearside Biomedical, Inc. (NASDAQ: CLSD) are skyrocketing Tuesday morning after the company announced positive safety results for a treatment for eye diseases. If Clearside makes it to the $4...
Clearside Biomedical Shares Soar On Encouraging Safety Profile For Injectable Axitinib In Wet AMD Patients
Clearside Biomedical Inc (NASDAQ: CLSD) has announced positive safety results from Cohort 1 (n=6) of OASIS Phase 1/2a trial of CLS-AX (axitinib injectable suspension) for neovascular age-related macular...
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (ax...
- CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events -
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in June 2021
ALPHARETTA, Ga., June 09, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve visio...
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide supra...
PDUFA Action Date Is October 30 , 2021 LAVAL, QC and ALPHARETTA, Ga., June 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global ey...
Recap: Clearside Biomedical Q1 Earnings
Shares of Clearside Biomedical (NASDAQ:CLSD) rose after the company reported Q1 results. Quarterly Results Earnings per share decreased 85.71% over the past year to ($0.13), which missed the estimate of...